Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza

@article{Bae2020PyronaridineAA,
  title={Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza},
  author={Joon-Yong Bae and Gee Eun Lee and Heedo Park and Juyoung Cho and Yung-Eui Kim and Joo-Yeon Lee and Chung Ju and Won-Ki Kim and Jin Il Kim and Man-Seong Park},
  journal={bioRxiv},
  year={2020}
}
Since the first human case was reported in Wuhan Province, China in December 2019, SARS-CoV-2 has caused millions of human infections in more than 200 countries worldwide with an approximately 4.01% case-fatality rate (as of 27 July, 2020; based on a WHO situation report), and COVID-19 pandemic has paralyzed our global community. Even though a few candidate drugs, such as remdesivir (a broad antiviral prodrug) and hydroxychloroquine, have been investigated in human clinical trials, their… 

Pyronaridine Protects Against SARS-CoV-2 in Mouse

Pyronaridine, an antiviral drug with in vitro activity against Ebola, Marburg and SARS-CoV-2 has now statistically significantly reduced the viral load in mice along with IL-6, TNF-α, and IFN-β ultimately demonstrating a protective effect against lung damage by infection to provide a new potential treatment for testing clinically.

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms

Tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC50 values of 180 nM and IC50 198 nM, respectively and novel insights are provided into the mechanism of these compounds which is likely lysosomotropic.

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV

11 molecules consisting of nelfinavir, favipiravir, azithromycin, clofoctol, cl ofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

Tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC50 values of 180 nM and IC50 198 nM, respectively and novel insights are provided into their mechanism which is likely lysosomotropic.

Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?

There is now sufficient evidence in the literature to suggest the effectiveness of Artemisia, its constituents and/or artemisinin derivatives, to fight against the SARS-CoV-2 infection by inhibiting its invasion, and replication, as well as reducing oxidative stress and inflammation, and mitigating lung damage.

Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants

Artemisia annua extracts inhibit SARS-CoV-2 infection, and the active component(s) in the extracts is likely something besides artemisinin or a combination of components that block virus infection at a step downstream of virus entry.

Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants

The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19

25 small molecule drugs that are either approved, in the process of approval or in the pipeline for COVID which have both in vitro and in vivo data are summarized and it is demonstrated that these drugs are structurally diverse and cover a wide chemistry space.

Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review

A review of potential anti-COVID-19 therapeutics that block/inhibit the post-entry stages of the viral life cycle and their anti-inflammatory/immune-modulatory effects aimed at catalyzing their potential effective use in fighting the pandemic.

The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time

Remdesivir, tocilizumab, and dexamethasone are some of the treatment options that have shown the most promise, but further randomized trials are required to particularly address timing and dosages to confidently create standardized protocols.

References

SHOWING 1-10 OF 10 REFERENCES

Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection

Studies with pyronaridine clearly demonstrate potential utility for its repurposing as an antiviral against EBOV and merits further study in larger animal models with the added benefit of already being used as a treatment against malaria.

The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.

The antiviral activities of artemisinin and artesunate.

Analysis of the complete profile of the pharmacological activities and molecular modes of action of artemisinin and artesunate and their performance in clinical trials will further elucidate the full antimicrobial potential of these versatile pharmacological tools from nature.

Repurposing Pyramax® for the Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine and Non-Lysosomotropic Artesunate

It is demonstrated in vitro that pyronaridine tetraphosphate is an inhibitor of Lysotracker accumulation in lysosomes and may represent a unique example of the repurposing of a combination product for another disease.

In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

These findings provide substantial evidence that AL and ASAQ are highly efficacious for the treatment of uncomplicated malaria in children in Burkina Faso and advocate the need to regularly replicate such surveillance studies.

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

  • V. CormanO. Landt C. Drosten
  • Medicine, Biology
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
  • 2020
A validated diagnostic workflow for 2019-nCoV is presented, its design relying on close genetic relatedness of 2019- nCoV with SARS coronavirus, making use of synthetic nucleic acid technology.

Artesunate Protects Against Sepsis-Induced Lung Injury Via Heme Oxygenase-1 Modulation

Findings suggest an effective and applicable treatment to sepsis-induced lung injury and provide new insights into the molecular mechanisms and actions of artesunate.

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).

Patients who received hydroxychloroquine for the treatment of pneumonia associated with COVID-19 were at high risk of QTc prolongation, and concurrent treatment with azithromycin was associated with greater changes in QTC.

WHO (2020) World Health Organization